NEW ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) AVAILABLE TO TREAT DIABETES AND GLAUCOMA ON THE NHF CARD DRUG LIST
August 12, 2019
As of July 31, 2019, five new Active Pharmaceutical Ingredients (APIs) have been made available through the National Health Fund for the treatment of diabetes and glaucoma for NHFCard Holders.
The new ingredients introduced for the treatment of diabetes are Dapagliflozin, Canagliflozin, Empagliflozin and Dapagliflozin/Metformin, while Brinzolamide/Brimonidine is geared towards the treatment of glaucoma. Dapagliflozin, which is available in the form of Forxiga tablets, can be accessed with an NHF subsidy of $58.75 per 5mg 30pk and $117.50 per 10mg 30 pk. Canagliflozin, available in the form of Invokana 100mg and 300mg tablets are subsidised at $61 and $183 respectively.
Jardiance tablets contain the API Empagliflozin and are available in 10mg and 25mg formulations with an NHF Subsidy of $59.55 and $148.88 respectively, while Dapagliflozin/Metformin appears under the Xigduo XR label with a subsidy of $60.54 for 5mg tablets and $124.06 for 10mg tablets. Available now under the NHFCard for the treatment of Glaucoma is Simbrinza Eye Drops containing the API Brinzolamide and Brimonidine enjoying a subsidy of $1,989.63.
Thousands of persons are expected to be impacted by the expansion of drug offerings given the total numbers enrolled on the NHFCard programme which amount to 177, 259 persons for diabetes and 64,876 for Glaucoma.
The decision to introduce the new drugs was influenced by the NHF’s mission to further expand the availability of treatment options as well as the additional health benefits to be derived from the new formulations.
Contact: Shermaine Robotham, Health Promotion and Public Relations Manager,
Health Promotion & Public Relations Department
Telephone numbers: 876-906-1106 or 876-832-8675
Visit www.nhf.org.jm or Follow us on Twitter, IG and FB @nhfjamaica